Navigation Links
Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted

ORLANDO, Fla., Feb. 24 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, is pleased to report that the Superior Court of Pennsylvania has dismissed the appeal filed by the Company's former CEO and President, John DePhillipo, and his wife against the Company, its subsidiary GeneWize Life Sciences, Inc., and several of the Company's officers, directors and advisors.  The Court also awarded sanctions in favor of the GeneLink Parties against the DePhillipos and their counsel, with the amount of such sanctions to be determined in the future by the Court of Common Pleas of Pennsylvania, Philadelphia County.  

The DePhillipos' appeal arose from the May 5, 2009 Order and Opinion of the Court of Common Pleas of Pennsylvania, Philadelphia County wherein that Court dismissed the DePhillipos' claims as unviable.  

About GeneLink BioSciences, Inc.:

GeneLink Biosciences is a genomics, biotechnology, and wellness company engaged in genetic profile development, product development, business development and support services for its subsidiaries and distribution partners.  GeneLink's patented and patent pending technologies include proprietary genetic assessments and products linked to personalized health, beauty and wellness applications. For additional information, please visit  

About GeneWize Life Sciences, Inc.:

GeneWize is a wholly owned subsidiary of GeneLink Biosciences and is the first network sales company to focus on providing individually customized nutritional and skin care formulations based on a consumer's personal DNA assessment.  The company's mission is to empower individuals to take personal responsibility and control of their health.  For additional information, please visit:

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE GeneLink, Inc.

Back to top



SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Insmed to Appeal Delisting Notification From Nasdaq
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
7. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
8. Court of Appeals Overturns 2005 Patent Verdict Against Cordis
9. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
10. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
11. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):